Concepts and applications for evidencebased dosing in. Jun 2 the complete but practical guide to vancomycin dosing. Therapeutic concentrations of 20 to 30 mgl were obtained in 54% of patients after 24 h. These results implied that tbw should be used to calculate vancomycin doses for morbidly obese patients. Vancomycin dosing for adults university health system. No morbidly obese patients and one control patient died in hospital p 0. Comparison of initial warfarin response in obese patients.
However, the ratio of lean body weight to total body weight decreases with increase in total body weight. Ketamine guideline for icp control in adults university. So some pharmacists will use adjusted body weight in. This can lead to undertreatment, and increased monitoring is recommended.
As pharmacists see more obese patients and pharmacotherapy becomes increasingly complex, they need a resource that puts all the necessary information in one place and makes it easy to use. Similarly, the guideline for the treatment of methicillin. Its ok to give 1 g of vancomycin, as long as the patient is obese and the dosing interval is adjusted to follow the 2compartment distribution model. Patients with morbid obesity had nonstatistically significant increases in length of postoperative intensive care stay, hospital. All subjects received a dose of 4 mgkg total body weight tbw by intravenous infusion 30 minutes. Our findings suggest that initial vancomycin dosing based on ibw rather than abw is a better predictor of steadystate vancomycin trough concentration in adult patients with severe or morbid obesity bmi. Aims for vancomycin treatment in obese patients, there is no consensus. For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target auc 400700 mgh l1. Vancomycin dosing, administration and monitoring guidelines for. Surgeons and anaesthetists need to be aware of these risks and consider the location of the procedure and postoperative care to achieve the best outcomes for patients. Liposomal amphotericin b ambisome pharmacokinetics given as a single intravenous dose to obese patients aspen the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Actual weight should be used when dosing vancomycin in obese and overweight patients. Obese patients have increased total body weight, with increases in both fat body weight as well as lean body weight.
Resuscitation of the morbidly obese patient sciencedirect. Volume 2 issue 2 2015 guniz m koksal and emre erbabacan department of anesthesiology and reanimation, istanbul university cerrahpasa medical school, turkey corresponding author. Adult antimicrobial weight based dosing drug dosing weight dosing weight in obesity vancomycin total body weight total body weight. In this article, an infectious diseases and critical care pharmacist with significant experience in this area is. Among other factors, obese patients have relatively more fat and less lean tissue per kilogram of total. Most vancomycin dosing guidelines in use today recommend dose adjustments based on totalbody weight which may not be ideal for obese and super obese patients. Jun 15, 2018 unfractionated heparin dosing for venous thromboembolism in morbidly obese patients. Implementation of idms standardization of creatinine is now almost complete in the united states through the effort of the national kidney disease education program. These findings challenge the current recommendation of calculating initial. Antibiotic dosing in obesity scottish antimicrobial prescribing group. Morbidly obese patients total body weight tbw 165 kg, ideal body weight ibw 63 kg required. Characteristics of patients with morbid obesity at an academic. The dosing of antibiotic agents in obese patients is challenging due to the inability to.
Pharmacokinetics in obese patients bja education oxford. Page 7 of 10 clinical setting empiric therapy duration comments. Article information, pdf download for vancomycin dosing in obese patients. We studied 45 morbidly obese body mass index 40 kgm 2 adults scheduled for gastric bypass surgery. Adult antimicrobial weight based dosing drug dosing weight dosing weight in obesity. In terms of vancomycin dosing kinetics, its an important question. The complete but practical guide to vancomycin dosing. Dosage requirements for morbidly obese patients with renal dysfunction require further study. Morbid obesity can be defined by a bmi 40, or bmi 35 with comorbid diseases such as dm and hypertension. Tbw dosing in obese patients can result in excessively high remifentanil concentrations, causing sideeffects such as apnoea, chest rigidity, bradycardia and hypotension. With demystifying drug dosing in obese patients, that resource is here, delivering. Individualized vancomycin dosing in obese patients. J0048 surgical prophylaxis with antibiotics in obese.
Drug dosing for overweight and obese patients sch this document reflects what is currently regarded as safe practice. Drug dosing for overweight and obese patients sch date of publishing. The fixed dose modeling showed similar auc024ss, cmaxss, and cminss between the groups. Various studies have attempted to address the conundrum of weightbased dosing in obese patients. Paracetamol vd is increased in obesity and in males relative to females. This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and non obese individuals, in order to guide vancomycin dosing in the obese. As the prevalence of obesity increases worldwide, an increasing number of obese surgical patients will require anesthesia. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Furthermore, in nomograms that incorporate body weight, it is unclear whether. Larger vancomycin doses for all patients are required to reach target trough serum concentrations. Purpose an original and a revised vancomycin dosing protocol for obese patients were compared with respect to attainment of target serum trough vancomycin concentrations and. To evaluate the effectiveness of a new vancomycin dosing protocol in morbidly obese patients in achieving therapeutic trough concentrations between 10 and 20 mcgml and to determine patient specific factors influencing the trough concentration attained.
Levofloxacin was administered at an actual body weightadjusted dose of 4 mgkg12 h based on a ciprofloxacin dosage recommendation for obese patients. Pdf an evaluation of systemic vancomycin dosing in obese. A practical downfall of the calculation of lean body weight and other body size descriptors is the numerical complexity, which may not be palatable to a busy clinician. Knowledge of the altered pharmacological behaviour of anaesthetic drugs is essential for optimal management of the morbidly obese. The authors describe the therapeutic drug monitoring of vancomycin in a man who is morbidly obese. Out of the 4381 patients who had cardiac surgery, 28 patients were morbidly obese 0. Vancomycin dosing in morbidly obese patients springerlink. For morbidly obese patients, consider drawing first level sooner e. However, vancomycin dosing nomograms have not been studied in patients who are morbidly obese. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
Morbidly obese patients require special dosing regimens. Obesity and morbid obesity are associated with several patho physiological changes that may influence the pharmacokinetics of drugs. Clearance increases with body weight and therefore is much greater in obese patients and. Knowledge of pharmacokinetics and pharmacodynamics of different antibiotics will assist with dosing. Antibiotic dosing in obese pati ents can be a major challenge. Like enoxaparin, the prophylactic dose should be increased in morbid obesity, for example 5000 units three times a day or 7500 units twice daily. This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to guide vancomycin dosing in the obese. Optimizing vancomycin dosing in obese and morbidly obese. Population pharmacokinetics of vancomycin in obesity. Vancomycin pharmacokinetics in normal and morbidly obese. Levofloxacin weightadjusted dosing and pharmacokinetic. An evaluation of systemic vancomycin dosing in obese patients.
However, as in any clinical situation, there may be. Whereas many of these manifest as advanced disease entities, some manifest as the most basic of health status deficiencies including the inability to bathe, dress, walk, and eliminate waste from the body independently. In 2002, scholten et al compared enoxaparin 30 mg twice daily vs enoxaparin 40 mg twice daily in a population consisting of 481 patients. Outcomes of the morbidly obese having cardiac surgery. Obesity is typically defined by body mass index bmi, the ratio of weight in kilograms to the square of height in meters calculator 1. Vancomycin loading doses in morbidly obese patients 2009. Drug information centerkauh drug dosing in obesity drug name type of weight obese adults acyclovir ibw ibw amikacin in underweight and nonobese patients, use of total body weight tbw instead of ideal body weight for determining the initial mgkgdose is widely accepted nicolau, 1995. For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target area under the curve 400700 mg h l. Ideal body weight ibw also may be used to determine. Finding the optimal dose for morbidly obese individuals. We assessed the performance of a novel, obese specific, dividedload vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients. Calculated doses should be rounded to the nearest 250mg for ease of dose preparation.
In this article, an infectious diseases and critical care pharmacist with significant experience in this area is interviewed and insights on the topic are provided. However, accurate measurement of lbw in morbidly obese is relatively difficult under normal clinical circumstances and few studies have used it as a dosing scalar 14. We conducted a prospective study of 18 adult volunteers maletofemale ratio of 1 whose body mass index fell into categories of 40 kgm2, who received a single oral dose of. Statement nonbariatric surgery on the obese patient carries with it complexities and risks.
Vancomycin dosing for adults university health system necessary patient information for dosing actual body weight the use of actual body weight is recommend for vancomycin dosing crcl vancomycin is almost exclusively renally cleared and must be renally adjusted o crcl 140age x wt in kg x 0. Daptomycin pharmacokinetics were studied in adult volunteers who were moderately obese body mass index bmi 2539. Use care when selecting patients for q8h dosing recommend to avoid in patients that are older andor with multiple co morbidities ex. Because serum vancomycin concentration svc monitoring continues to be deemphasized, nomogram use will likely increase. Vancomycin hydrochloride dosing requirements in morbidly obese patients with normal renal function were computed to determine the dose of vancomycin necessary to achieve target steadystate peak and trough concentrations and compared with a normal weight population. At this time, initial vancomycin dosing for patients who are overweight or obese should not be different from dosing for healthyweight patients. The results of the study described here demonstrate that obese patients may benefit from a vancomycin dosing strategy different from that generally recommended for adult patients with normal renal. Pdf we retrospectively identified 67 patients with severe or morbid obesity body mass index. As vancomycin dosing in our institution is managed by a pharmacist for the majority of. Vancomycin dosing in obese and morbidly obese patients. Optimizing vancomycin dosing in obese and morbidly obese patients.
Morbidly obese, awake patients are generally hypoxemic with a widened aa gradient. Dose adjustment of anaesthetics in the morbidly obese. We retrospectively identified 67 patients with severe or morbid obesity body mass index. To evaluate the effectiveness of a new vancomycin dosing protocol in morbidly obese patients in achieving therapeutic trough concentrations between 10 and 20 mcgml and to determine. Extrapolation of results from one patient population to. Comprehensive guidance for antibiotic dosing in obese. Vancomycin iv see umhs standard dosing nomogram, 1015 goal trough 57 days close clinical followup is recommended, especially in patients no receiving antibiotic. Key words vancomycin obesity pharmacokinetic variability. Performance of a dividedload intravenous vancomycin. Vancomycin dosing in morbidly obese patients deepdyve. Some antibiotics may require higher doses at the same frequency, whereas others may require more frequent dosing. Induction of ketamine therapy facultyphysician supervised.
In 2012, the croes pcnl global study discussed the influence of bmi on the outcome of pcnl and showed that pcnl may be done safely in obese patients but with a longer operation time, lower stone free rates and higher reintervention rates,6 but did not include the middle. Pharmacokinetics of vancomycin in extremely obese patients. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed staphylococcus aureus infections. To date, no published protocol reliably meets these recommendations for obese patients. Consider q8h if patient 100 mlmin notes avoid every 18 hour and every 36 hour dosing intervals as these are errorprone round all doses to the nearest 250 mg maximum vancomycin dose 2g dose. Adult antimicrobial weight based dosing drug dosing weight. Antibiotic dosing in obese patients can be a major challenge. The fda has not recognized obese patients as a special population and thus pharmacokinetic studies to determine appropriate dosing is not required in this population. Vancomycin has been in clinical use since the 1950s.
Calculated doses should be rounded to the nearest 250mg for ease of dose. Lukes boise and meridian vancomycin dosing guidelines for obese patients. No maximum daily dose patients with a dose 3gday have increased risk of nephrotoxicity. Morbidly obese patients, both in acute care and in home health, have a complex array of physical and psychological stressors. Vancomycin clearance in overweight and obese patients. The majority of data pertaining to the dosing of lmwh in obese patients for vte prophylaxis has been collected from patients undergoing bariatric surgery, with enoxaparin being the most common agent assessed. However, nomograms often use a dose cap bolus and maintenance in obese patients. Jun 29, 2017 new anesthesia dosing models may increase safety of remifentanil for obese patients and children. Fullyreferenced dosing recommendations for specific drugs. The response to ulnar nerve stimulation of the adductor pollicis muscle at the wrist was recorded using the tofwatch sx acceleromyograph.
Using this data in simulations, one study found low pta with 2 g iv every 12 hour dosing, leading the authors to recommend 2 g every 8 hour dosing in morbidly obese patients table s2. Unfractionated heparin dosing for venous thromboembolism in. Vancomycin pharmacokinetics in critically ill obese. Evaluation of a new vancomycin dosing protocol in morbidly. Therapeutic drug monitoring of vancomycin in a morbidly. Prevention of deep wound infection in morbidly obese patients by. Apr 02, 2012 this guide for patients is based on asco recommendations and is intended for people who are obese. For the monte carlo simulation, with the use of tbw dosing, the auc 024ss, c maxss, and c minss were 2fold higher in morbidly obese patients compared with nonobese patients. The pharmacokinetics of daptomycin in moderately obese.
Liposomal amphotericin b ambisome pharmacokinetics given as. Evaluation of a vancomycin dosing nomogram in obese patients. Apr 07, 2020 performance of a vancomycin dosage regimen developed for obese patients. Consequently, the clearance of vancomycin, a renally eliminated drug, has been shown to be accelerated in morbidly obese patients. A new formula has been developed see table 3 that appears stable across different body sizes, in particular the obese to morbidly obese. A vancomycin dosage regimen developed for obese patients. Drug information centerkauh drug dosing in obesity drug name type of weight obese adults acyclovir ibw ibw amikacin in underweight and nonobese patients, use of total body weight tbw instead of ideal body weight for determining the initial mgkg dose is widely accepted nicolau, 1995. Due to the variability in dosing of obese patients compared to non obese patients, vcn maximum doses and the incidence of nephrotoxicity will also be discussed. Vancomycin dosing in healthyweight, overweight, and obese. New anesthesia dosing models may increase safety of. Vancomycin dosing in obesity morganne smyth, pharm. While total body weight is generally good for most patients, it might lead to problems in morbidly obese patients. The appropriate dose of succinylcholine sch in morbidly obese patients is unknown. Weightbased dosing recommendations for intravenous.
930 370 957 192 499 350 51 1249 1184 498 886 1233 413 1457 1024 1435 1415 61 1248 510 1187 227 905 1138 527 857 1190 745 1354 81 365 123 1019 148 728 690 784 1056 1287 470 1491 123 566 1362 1458 1329 1155